



(43) International Publication Date
9 January 2014 (09.01.2014)

(10) International Publication Number
WO 2014/005959 A1

(51) International Patent Classification:

A61K 39/245 (2006.01) C12N 7/02 (2006.01)
C07K 14/045 (2006.01)

(21) International Application Number:

PCT/EP2013/063750

(22) International Filing Date:

29 June 2013 (29.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/668,975 6 July 2012 (06.07.2012) US
61/770,257 27 February 2013 (27.02.2013) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
CH-4056 Basel (CH).

(72) Inventors: **CARFI, Andrea**; c/o Novartis Vaccines and
Diagnostics, Inc., 350 Massachusetts Avenue, Cambridge,
Massachusetts 02139 (US). **WEN, Yingxia**; c/o Novartis
Vaccines and Diagnostics, Inc., 350 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US).

(74) Agents: **EVANS, Stephen John Eves** et al.; Novartis Vac-
cines and Diagnostics S.r.L., Via Fiorentina 1, I-53100 Si-
ena (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPLEXES OF CYTOMEGALOVIRUS PROTEINS

(57) Abstract: This disclosure provides an isolated human cytomegalovirus (HCMV) membrane protein complex, wherein said complex comprises gH, gL and at least one more HCMV glycoprotein. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, p UL128, p UL130 and p UL131A. The disclosure also provides processes for expressing and purifying said complexes, and subsequent uses of said complexes in immunogenic compositions and vaccines.



WO 2014/005959 A1